206 completed, 27 unknown, 13 terminated, 11 withdrawn. 79 Phase 4, 74 Phase 3, 49 Phase 2, 34 Phase 1, 27 Not applicable.
Follow Exenatide: new trials by email Literature Review of Exenatide trials Research Report on Exenatide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant Exenatide Implant, Bydureon BCise (exenatide extended release), Semaglutide, 1.0 mg/mL - Overweight and Obesity, Type2diabetes | Phase 1 | Completed | Vivani Medical, Inc | 24 | 2024-12-20 | 2025-09-23 |
| A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs Exenatide, Non-GLP-1 RA based glucose lowering drugs - Pancreatic Cancer | Recruiting | AstraZeneca | 24000 | 2024-09-30 | 2026-09-24 | |
| Exenatide For Reducing the Reinforcing Effects of Cocaine Exenatide, Placebo - Cocaine Use Disorder | Phase 1 | Withdrawn | Christopher D. Verrico | 2024-08-01 | 2026-03-13 | |
| Diabetes Islet Preservation Immune Treatment Anti-Thymocyte Globulin (ATG), Interleukin 2, Exenatide - Diabetes Mellitus, Type 1, Hypoglycemia | Phase 1 / Phase 2 | Withdrawn | Camillo Ricordi and Jay Skyler | 2024-06-01 | 2026-01-15 | |
| Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD GLP-1 receptor agonist, SGLT2 inhibitor, Tirzepatide - Chronic Kidney Disease stage3, Chronic Kidney Disease stage4 | Recruiting | Cardenal Herrera University | 250 | 2023-09-15 | 2025-12-30 | |
| Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes Exenatide - Gestational Diabetes | Phase 4 | Recruiting | Maisa N. Feghali, MD | 13 | 2023-04-12 | 2026-04-20 |
| Exenatide for Smoking Cessation and Prevention of Weight Gain Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch - Smoking Cessation, Weight Gain | Phase 2 | Completed | The University of Texas Health Science Center, Houston | 140 | 2022-12-07 | 2026-03-23 |
| Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes 0.9% Sodium-chloride, Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min, Glucagon 12.5ng/kg/min and 0.9% saline - Type 2 Diabetes, Obesity | Phase 4 | Completed | Cambridge University Hospitals NHS Foundation Trust | 10 | 2022-01-18 | 2024-09-19 |
| Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) Experimental: GLP1-RA (exenatide) administration, Control: Placebo administration - Hypopituitarism, Central Diabetes Insipidus | Phase 4 | Completed | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 42 | 2021-09-13 | 2026-01-20 |
| Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA - Cardiovascular Events, Type2 Diabetes | Active not recruiting | Brigham and Women's Hospital | 781430 | 2021-08-01 | 2026-08-13 | |
| Comparison of Type 2 Diabetes Pharmacotherapy Regimens SU, DPP4, SGLT2i - Type 2 Diabetes Mellitus, Cardiovascular Diseases | Completed | Kaiser Permanente | 241981 | 2021-07-01 | 2025-11-21 | |
| Exenatide for Treating Cocaine Use Disorder Exenatide 2 mg [Bydureon], Drug Counseling - Cocaine Use Disorder | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center, Houston | 3 | 2021-06-24 | 2022-06-27 |
| Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia Exenatide, 0.9% saline solution - Endogenous Hyperinsulinism | Not applicable | Completed | University Hospital, Basel, Switzerland | 29 | 2021-04-29 | 2024-05-08 |
| Brain Activation and Satiety in Children 2 Family Based Behavioral Treatment, Exenatide 2 mg [Bydureon], Placebo - Childhood Obesity | Phase 3 | Active not recruiting | Seattle Children's Hospital | 63 | 2021-01-28 | 2026-01-05 |
| Effects of GLP-1 Analogue Combined With Metformin and Metformin on Gonadal and Metabolic Profiles in Chinese Overweight/Obese PCOS Patients With Hyperandrogenemia. Metformin, Exenatide - Polycystic Ovary Syndrome | Phase 4 | Completed | Bing He | 60 | 2021-01-04 | 2022-04-14 |
| Exenatide Once-weekly as a Treatment for Multiple System Atrophy Exenatide Pen Injector [Bydureon] - Multiple System Atrophy | Phase 2 | Completed | University College, London | 50 | 2020-09-16 | 2025-06-27 |
| Exenatide Treatment in Parkinson's Disease Exenatide, Placebo - Parkinson Disease | Phase 2 | Unknown | Center for Neurology, Stockholm | 60 | 2020-01-21 | 2022-09-13 |
| Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease Exenatide extended release 2mg (Bydureon) - Parkinson's Disease | Phase 3 | Completed | University College, London | 194 | 2020-01-20 | 2026-05-06 |
| The Effect of Exenatide on Fasting Bile Acids Exenatide treatment - Type 2 Diabetes Mellitus in Obese | Completed | Beijing Chao Yang Hospital | 38 | 2020-01-05 | 2020-06-11 | |
| Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients Metformin, Exenatide 2 MG - Polycystic Ovary Syndrome | Phase 4 | Unknown | Peking Union Medical College Hospital | 80 | 2019-07-20 | 2019-07-23 |
Showing 20 of 263. Sign in to see all of them.
Diabetes Mellitus, Type 2 (148) · Diabetes Mellitus (67) · Obesity (35) · Diabetes Mellitus, Type 1 (14) · Insulin Resistance (14) · Glucose Intolerance (12) · Weight Loss (7) · Hyperglycemia (6) · Hypoglycemia (6) · Overweight (6) · Polycystic Ovary Syndrome (6) · Myocardial Infarction (5) · Non-alcoholic Fatty Liver Disease (5) · Parkinson Disease (5) · Sexual Infantilism (5)
AstraZeneca (59) · Intarcia Therapeutics (14) · Amsterdam UMC, location VUmc (5) · Novo Nordisk A/S (5) · Baylor College of Medicine (4) · GlaxoSmithKline (4) · The University of Texas Health Science Center at San Antonio (4) · The University of Texas Health Science Center, Houston (4) · University College, London (4) · Yale University (4) · Beijing Chao Yang Hospital (3) · Canadian Network for Observational Drug Effect Studies, CNODES (3) · Seattle Children's Hospital (3) · University at Buffalo (3) · University of Minnesota (3)
United States (140) · United Kingdom (21) · China (20) · Germany (18) · Canada (17) · Denmark (16) · Netherlands (15) · Spain (14) · Mexico (13) · France (12) · Italy (12) · Sweden (12) · Finland (11) · Puerto Rico (10) · South Korea (10)
James Malone, MD (17) · Lisa Porter, MD (8) · Aaron S. Kelly, Ph.D. (3) · Luba Yammine, PhD (3) · Pierre Ernst, MD, MSc (3) · Eleftheria Maratos-Flier, MD (2) · Jose Oberholzer, MD (2) · Mandeep Bajaj, MD (2) · Michael Camilleri, MD (2)
PMID 22236356, PMID 22913891, PMID 39963952, PMID 17705687, PMID 23748506, PMID 28286967, PMID 15353407, PMID 15504997, PMID 15855571, PMID 15855572, PMID 16230722, PMID 16776749, PMID 16776751, PMID 17098089, PMID 17160407, PMID 17379054, PMID 17404349, PMID 17595353, PMID 17622601, PMID 18053320, PMID 18394265, PMID 18444920, PMID 18460557, PMID 18662495, PMID 18782641, PMID 18786299, PMID 18803987, PMID 19019476, PMID 19194050, PMID 19196887, PMID 19210140, PMID 19245711, PMID 19446153, PMID 19491536, PMID 19515413, PMID 19808924, PMID 19930005, PMID 20107105, PMID 20109208, PMID 20152707, PMID 20189026, PMID 20200309, PMID 20215461, PMID 20332351, PMID 20332357, PMID 20332358, PMID 20357372, PMID 20452396, PMID 20494360, PMID 20557887
2014 (3), 2015 (2), 2016 (2), R01DK077166 (2), 2008 (1), 2009 (1), 2018 (1), K01HL092585 (1), K23DK075931 (1), K23DK107871 (1), P30AI054999 (1), R01DK067071 (1), R01DK107680 (1), R01NS052318 (1), R21AA027332 (1)